Encouraging Early Data Reported in Severe Heart Failure Patients With Dilated Cardiomyopathy

Aastrom Has Until September 18, 2009 to Regain Compliance

ANN ARBOR, Mich., March 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today commended the expansion of federal support designed to advance stem cell research.

Trial to Resume At Four Clinical Sites for Patients Suffering From Dilated Cardiomyopathy

Continued Clinical Progress Reported From Cardiovascular Programs

ANN ARBOR, Mich., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George W. Dunbar, President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference.

ANN ARBOR, Mich., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported that one patient enrolled in the Company's U.S. Phase II IMPACT-DCM clinical trial experienced a serious adverse event associated with anesthesia

ANN ARBOR, Mich., Nov. 20, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the first patient has been treated in its randomized, controlled, prospective, open-label IMPACT-DCM clinical trial.

ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the first fiscal quarter ended September 30, 2008. The Company also reported several recent clinical and operational

ANN ARBOR, Mich., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Martin C. Peters, PhD, Senior Director, Business Strategy & Market Development, will present at the Rodman & Renshaw 10th Annual Healthcare